{"id":411274,"date":"2026-04-22T06:06:15","date_gmt":"2026-04-22T06:06:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/411274\/"},"modified":"2026-04-22T06:06:15","modified_gmt":"2026-04-22T06:06:15","slug":"15-2m-valsartan-losartan-and-irbesartan-class-action-settlement","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/411274\/","title":{"rendered":"$15.2M Valsartan, Losartan and Irbesartan class action settlement"},"content":{"rendered":"

Aurobindo, Hetero and Vivimed agreed to class action settlements totaling more than $15.2 million to resolve claims that their blood pressure medications were contaminated with cancer-causing substances.<\/p>\n

Aurobindo agreed to a $2 million class action settlement, Hetero a $11,365,489.80 settlement and Vivimed a $1,899,000 settlement to resolve claims that their irbesartan, valsartan and losartan blood pressure medications were contaminated with cancer-causing substances.<\/p>\n

All three class action settlements are part of the same larger federal litigation \u2014 In re: Valsartan, Losartan and Irbesartan Products Liability Litigation \u2014 currently pending in the United States District Court for the District of New Jersey.<\/p>\n

The Aurobindo settlement benefits consumers who paid for irbesartan medications manufactured with Aurobindo irbesartan active pharmaceutical ingredient (API) since Jan. 1, 2016. The Hetero settlement benefits consumers who paid for valsartan medications manufactured using Hetero Process III API sold between May 1, 2018, and July 31, 2018. The Vivimed settlement benefits consumers who paid for Vivimed losartan finished drug formulations sold under specific impacted National Drug Codes (NDCs).<\/p>\n

The class action lawsuit<\/a> claimed that medications from pharmaceutical manufacturers Aurobindo (irbesartan), Hetero (valsartan) and Vivimed (losartan) were contaminated with nitrosamine impurities \u2014 NDEA, NDMA and NMBA, respectively \u2014 all alleged to be human carcinogens.<\/p>\n

The plaintiffs in the cases say that each manufacturer knew or should have known that its medication was contaminated with these impurities. However, the companies allegedly failed to warn consumers and retailers about the contamination. As a result of each defendant\u2019s alleged failure to warn, consumers were forced to overpay for the contaminated medications.<\/p>\n

Aurobindo, Hetero and Vivimed have each denied any wrongdoing but agreed to resolve these allegations with their respective settlements.<\/p>\n

Under the terms of the Aurobindo class action settlement, class members can receive a cash payment based on the amount they paid for irbesartan medications. Class members who paid out of pocket for irbesartan medications can receive a reimbursement of up to $100. Class members who have documentation of their purchases can receive a larger reimbursement of up to $200.<\/p>\n

Under the terms of the Hetero settlement, consumers can generally receive up to $40 for each 30-day supply purchased, with a maximum total payment of $120. However, consumers who can sufficiently document purchases in excess of $40 for a 30-day supply may receive a higher payment without regard to the standard caps.<\/p>\n

Payment amounts for individual Vivimed class members have not yet been specified, as the allocation method is to be determined by class counsel and reviewed by the court prior to the final approval hearing.<\/p>\n

For the Aurobindo and Hetero class action settlements, the deadline for exclusion, objection and claim submission is June 2, 2026, and the final approval hearing is scheduled for June 30, 2026. Deadlines for the Vivimed settlement have not yet been set by the court.<\/p>\n","protected":false},"excerpt":{"rendered":"Aurobindo, Hetero and Vivimed agreed to class action settlements totaling more than $15.2 million to resolve claims that…\n","protected":false},"author":2,"featured_media":411275,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[104932,103,61,60,371],"class_list":{"0":"post-411274","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-featured-settlement","9":"tag-health","10":"tag-ie","11":"tag-ireland","12":"tag-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/411274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=411274"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/411274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/411275"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=411274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=411274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=411274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}